25%) was noted in patients with islet cell carcinomas who received HACE compared with patients who received HAE, although the differences did not reach statistical significance.
1
—
—
25%) was noted in patients with islet cell carcinomas who received HACE compared with patients who received HAE, although the differences did not reach statistical significance.